ND0612 is an investigational drug-device therapy that provides a 24-hour continuous subcutaneous infusion of levodopa/carbidopa solution. The Food and Drug Administration (FDA) has accepted for review ...

“The FDA’s decision to grant Fast Track designation for TEV-53408, an investigational anti-IL-15 antibody therapy, reflects the promising nature of the treatment and the urgent unmet need of people ...

In a recent interview on NBC News’ "Meet the Press," Murthy said Congress has failed to act on what he described as a growing crisis.

Findings seen for patients with extensive-stage small cell lung cancer, following standard induction therapy.

The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for sibeprenlimab for the treatment of immunoglobulin A nephropathy (IgAN) in adults.

The protest happened roughly 27 minutes into the meeting, held at NIH headquarters in Bethesda, Md. In a video obtained by CNN, Bhattacharya is shown telling staff that, based on his review of ...

The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis of the scalp and ...

The approval for interchangeability was supported by data from a phase 4 trial that assessed the pharmacokinetics, efficacy, safety, and immunogenicity of Hadlima vs Humira in patients with moderate ...

Prothena has made the decision to discontinue the AFFIRM-AL trial, including the open-label extension portion.

The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with ...

According to Makary and Prasad, the US’s adoption of a “one-size-fits-all” guidance for COVID-19 vaccination departs from other high income countries that limit recommendations to older adults or ...

The researchers found that after 64 weeks, participants had a mean weight loss of −16.7%, with a mean semaglutide dose of 1.08mg/week.